Lefamulin ( DrugBank: Lefamulin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05225805 (ClinicalTrials.gov) | March 1, 2022 | 7/1/2022 | Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis | A Phase 1, Open-Label, Randomized, Crossover Study to Assess the Safety and Pharmacokinetics Following Single Doses of Oral and Intravenous Xenleta (Lefamulin) in Adult Patients With Cystic Fibrosis | Cystic Fibrosis | Drug: Lefamulin | Nabriva Therapeutics AG | NULL | Completed | 18 Years | 80 Years | All | 13 | Phase 1 | United States |